i
Duration of protection against hepatitis A for the current two-dose vaccine compared to a three-dose vaccine schedule in children
-
Mar 05 2013
-
-
Source: Vaccine 31(17):2152-2155
[PDF-108.10 KB]
Details:
-
Alternative Title:Vaccine
-
Personal Author:
-
Description:Background
Hepatitis A is mostly a self-limiting disease but causes substantial economic burden Consequently, United States Advisory Committee for Immunization Practices recommends inactivated hepatitis A vaccination for all children beginning at age 1 year and for high risk adults The hepatitis A vaccine is highly effective but the duration of protection is unknown
Methods
We examined the proportion of children with protective hepatitis A antibody levels (anti-HAV ≥20 mIU/mL) as well as the geometric mean concentration (GMC) of anti-HAV in a cross sectional convenience sample of individuals aged 12–24 years, who had been vaccinated with a two-dose schedule in childhood, with the initial dose at least 5 years ago We compared a subset of data from persons vaccinated with two-doses (720 ELU) at age 3–6 years with a demographically similar prospective cohort that received a three-dose (360 ELU) schedule and have been followed for 17 years
Results
No significant differences were observed when comparing GMC between the two cohorts at 10 (P = 0467), 12 (P = 0496), and 14 (P = 0175) years post-immunization For the three-dose cohort, protective antibody levels remain for 17 years and have leveled-off over the past 7 years
Conclusion
The two- and three-dose schedules provide similar protection >14 years after vaccination, indicating a booster dose is not needed at this time Plateauing anti-HAV GMC levels suggest protective antibody levels may persist long-term
-
Subjects:
-
Source:
-
Pubmed ID:23470239
-
Pubmed Central ID:PMC4648811
-
Document Type:
-
Funding:
-
Place as Subject:
-
Location:
-
Volume:31
-
Issue:17
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
